Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s318332
Abstract: Abstract Erdafitinib received accelerated approval on April 12, 2019, for patients with metastatic or locally advanced urothelial carcinoma with susceptible fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations and who have progressed during… read more here.
Keywords: evidence selecting; clinical evidence; advanced urothelial; urothelial carcinoma ... See more keywords